Faculty of Life Science & Medicine, Northwest University, No. 229 Taibai North Road, Xi'an, Shaanxi 710069, China.
Department of Nephrology, Baoji Central Hospital, No. 8 Jiangtan Road, Baoji, Shaanxi 721008, China.
Clin Chim Acta. 2019 Apr;491:59-65. doi: 10.1016/j.cca.2019.01.008. Epub 2019 Jan 11.
Chronic kidney disease (CKD) results in high morbidity and mortality worldwide causing a huge socioeconomic burden. MicroRNA (miRNA) exert critical regulatory functions by targeting downstream genes and have been associated with many pathophysiologic processes including CKD. In fact, many studies have shown that the expression of various miRNAs was significantly changed in CKD. Current investigations have focused on revealing the relationship between miRNAs and CKD states including diabetic nephropathy, lupus nephritis, focal segmental glomerulosclerosis and IgA nephropathy. In this review, we summarize the latest advances elucidating miRNA involvement in the progression of CKD and demonstrate that miRNAs have the potential to be effective biomarkers and therapeutic targets for subsequent treatment.
慢性肾脏病（CKD）在全球范围内导致高发病率和死亡率，造成巨大的社会经济负担。微小 RNA（miRNA）通过靶向下游基因发挥关键的调节功能，与许多病理生理过程有关，包括 CKD。事实上，许多研究表明，miRNA 在 CKD 中的表达有显著变化。目前的研究重点是揭示 miRNA 与 CKD 状态之间的关系，包括糖尿病肾病、狼疮性肾炎、局灶节段性肾小球硬化和 IgA 肾病。在这篇综述中，我们总结了最新的进展，阐明了 miRNA 参与 CKD 进展的作用，并表明 miRNA 有可能成为有效的生物标志物和治疗靶点，用于后续治疗。
